Final Director's Interest Notice - Dr Elliott
3 November 2026 10:53
|
PolyNovo Limited is a medical device company that develops and commercializes synthetic skin substitutes using its patented bioabsorbable polymer technology, NovoSorb. The company's primary product, NovoSorb BTM (Biodegradable Temporizing Matrix), is designed to support tissue repair in patients with full-thickness burns before biodegrading in situ into biocompatible by-products. PolyNovo serves healthcare professionals and clinicians globally and has secured regulatory clearances including the US FDA 510(K), Australian TGA registration, and European CE Mark. The company holds a contract with the US Biomedical Advanced Research and Development Authority (BARDA) to complete a pivotal trial for burn treatment. PolyNovo’s technology originated from a collaboration with CSIRO and Prof. John Greenwood, with the first patient treated in 2013 and commercialization beginning in 2015 following US clearance. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Health Care Equipment & Services | Homepage polynovo.com |
| Sector Healthcare | IR page investors.polynovo.com | |
|
Tags
synthetic skin substitutes, burn treatment, bioabsorbable polymers, tissue repair, medical devices, wound care, NovoSorb, NovoSorb BTM, Biodegradable Temporizing Matrix
|
Press page — |
| Valuation | |
|---|---|
| Market cap | A$ 625.213M |
| Market cap (USD) | $ 429.569M |
| P/E | 86.79 |
| PEG | — |
| P/BV | 7.01 |
| P/S | 4.35 |
| P/OCF | 27.05 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | — |
| ROI | — |
| ROIC | — |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 4.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 33.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 143.706M | 127.243M | 103.192M | 65.241M | 41.44M | 29.158M | 22.156M | 13.349M | 5.714M | 3.759M | 3.471M | 140.721K | 244.577K |
| Net profit | — | — | 5.261M | — | -1.193M | -4.605M | -4.194M | -3.19M | -5.974M | -5.006M | -3.062M | -1.302M | -2.936M |
Sign up to see institutional holdings
Sign UpSign up to see podcast mentions and sentiment
Sign UpAnnouncements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
3 November 2026 10:53
3 November 2026 10:51
Final Director's Interest Notice - Ms Emmanuel-Donnelly (PDF)
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.